---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-003755"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2025-01-15T23:59:59+00:00"
generated_at: "2026-05-28T01:12:16.288988+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Entrada reports ~$420M cash; DMD pipeline advancing with multiple 2025 trial starts

## Summary
- Preliminary cash resources ~$420M as of Dec 31, 2024, extending runway into Q2 2027.
- Phase 1 ENTR-601-44 data: no treatment-related AEs; dose-dependent PK/PD and statistically significant exon skipping at 6 mg/kg.
- Plans to initiate Phase 1/2 MAD studies for ENTR-601-44, -45, -50, and -51 in 2025; Vertex advancing VX-670 MAD portion in DM1.
- Preclinical data show dose-dependent dystrophin restoration and functional correction in DMD mouse models across franchise.
- Cash and clinical updates based on preliminary unaudited estimates; year-end audit ongoing.

## SEC filing metadata
- accession: 0001104659-25-003755
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2025-01-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000110465925003755/0001104659-25-003755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000110465925003755/tm253290d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-003755
- JSON: https://secwatch.observer/filing/0001104659-25-003755.json
- Plain text: https://secwatch.observer/filing/0001104659-25-003755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.